Mendota Financial Group LLC Sells 195 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mendota Financial Group LLC lessened its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 30.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 455 shares of the company’s stock after selling 195 shares during the period. Mendota Financial Group LLC’s holdings in Neurocrine Biosciences were worth $62,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences during the second quarter worth about $28,000. Blue Trust Inc. boosted its holdings in shares of Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares during the period. Plato Investment Management Ltd lifted its position in Neurocrine Biosciences by 44.1% during the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after acquiring an additional 130 shares during the last quarter. Truvestments Capital LLC acquired a new stake in shares of Neurocrine Biosciences during the third quarter worth $63,000. Finally, True Wealth Design LLC increased its position in Neurocrine Biosciences by 11,740.0% during the third quarter. True Wealth Design LLC now owns 592 shares of the company’s stock worth $68,000 after acquiring an additional 587 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Buying and Selling at Neurocrine Biosciences

In related news, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This represents a 13.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Ingrid Delaet sold 272 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total value of $37,563.20. Following the sale, the insider now owns 2,507 shares of the company’s stock, valued at approximately $346,216.70. This represents a 9.79 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,694 shares of company stock valued at $479,230. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Up 1.5 %

NASDAQ:NBIX opened at $143.03 on Tuesday. The firm has a market capitalization of $14.48 billion, a P/E ratio of 38.35 and a beta of 0.33. Neurocrine Biosciences, Inc. has a twelve month low of $110.95 and a twelve month high of $157.98. The company has a fifty day moving average of $130.43 and a 200-day moving average of $131.01.

Analyst Ratings Changes

A number of research analysts have issued reports on NBIX shares. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Raymond James restated an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. Barclays increased their target price on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a report on Monday, December 23rd. Finally, BMO Capital Markets lowered their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research report on Thursday, October 17th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $164.81.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.